Medial EarlySign

More and more attention is being directed toward the fact that increasing numbers of young people are being diagnosed with #colorectalcancer (CRC) at an alarming rate. The popular media is now devoting more attention to the importance of #screening plus #earlydetection and intervention. This recent article from NBC News offers a good perspective and common-sense steps people can take to potentially avoid the complications and devastating consequences of CRC. #EarlyDetection #ColonCancer #AI https://lnkd.in/dcq_acwh

EarlySign’s efforts at validation of its LungFlag™ model continue to receive scientific recognition on a global scale. In the category of “Screening and Early Detection - Innovative Screening Technology,” EarlySign was selected to present a new poster at the recent 2024 World Conference on Lung Cancer in San Diego. Entitled “Validation of LungFlag™ Prediction Model Using Electronic Medical Records (EMR) on Taiwan Data,” the study was built with the knowledge that Lung cancer (LC) is the leading cause of cancer death according to the WHO. To reduce mortality rate, starting 2022, the Ministry of Health and Welfare in Taiwan launched the LC Early Detection Program to provide biennial low-dose computed tomography (LDCT) screening for high-risk groups. In conjunction with researchers at Roche and the National Taiwan University Hospital and College of Medicine in Taipei, the conclusions of the study demonstrated that #LungFlag™ was able to work on Taiwanese EMR data and presented superiority over criteria based selection of individuals (USPSTF) and performed better than gold standard benchmark risk model PLCOm2012 that was adapted to be used on EMR data . The results were comparable to the previous validation studies and indicates that LungFlag™ can immediately support Taiwan screening program in identifying elevated risk populations among ever-smokers and potentially also on never-smokers populations. #innovation #earlydetection #prescreening https://lnkd.in/gynRKDag

Medial EarlySign was pleased to be part of a team that delivered a poster presentation at the American Society of Clinical Oncology (ASCO) in June 2024. The research highlighted the development of a budget impact model based on the adoption of LungFlag™ (a validated clinical AI model) as an adjunct to existing screening guidelines for USPSTF-eligible patients. Using a hypothetical US health plan population of 1-million beneficiaries, there were 36,803 USPSTF-eligible persons for low-dose CT screening (LCS). Assuming 4,600 (12.5%) had already initiated LCS, that left 32,203 persons to be pre-screened by LungFlag, which was configured to select top 3% (990) for further assessment by LCS.  The use of Lung Flag on this population was estimated to prevent 22 additional NSCLC-related deaths, with a cost savings of $2.87 million over 5 years from a US commercial payer perspective. The poster provides additional details around total population size, screening eligibility, and more. In conjunction with researchers from Roche, Kaiser Permanente, and Genentech we are pleased to make this research available and support industry-wide efforts to demonstrate how AI models can have a truly beneficial impact on early detection of serious disease. We invite you to download the full Poster. https://lnkd.in/gQBMJkKH #earlydetection #clinicalAI

The Value of Clinical Labs in Early Detection, Precision Treatment Plans, and Effective Therapies In the highly complex and intricate landscape of healthcare, clinical laboratories often go unnoticed, yet their contribution is indispensable. These labs are the backbone of medical diagnostics, providing critical data that empowers physicians to make evidence-based decisions. Early detection can be a cornerstone component of effective treatment, and clinical labs are at the forefront of this effort. With advanced testing capabilities, they help identify serious diseases at their nascent stages, with the potential to significantly improve patient outcomes. From detecting cancer markers to identifying infectious agents, clinical labs play a pivotal role in the diagnostic process. The data generated by these labs enable physicians to tailor treatment plans with precision, ensuring that patients receive the most effective and personalized therapies. This synergy between lab scientists and physicians epitomizes the essence of personalized medicine, where treatments are not just reactive but proactive, and tailored to the individual needs of each patient. The Clinical Lab 2.0 framework supports that position that early detection strategies can be built on deployment of proactive risk stratification and finding care gaps which may ultimately lead to the earlier identification of high-risk patients for targeted intervention. As we strive towards a future where early detection and personalized medicine hopefully become the norm, the role of clinical labs will only grow in importance--driving forward the mission of saving lives and improving health. Clinical Lab 2.0 Ori Geva #PrecisionMedicine #EarlyDetection #HealthcareInnovation

We are pleased to expand our strategic partnership with Lucem Health as we work together to bring proven solutions to impact early detection for serious disease. Our collaboration demonstrates a shared vision of both companies to provide healthcare professionals with innovative tools to accelerate pathways to intervention.

For the first time, Newsweek and Statista have released their annual rankings of digital health companies. With clear and detailed methodology, the winners were selected based on financial performance, impact, and user engagement. EarlySign is pleased to be named amongst this distinguished group of health leaders making positive strides toward better health across the globe. https://lnkd.in/gsjf7JTU

Increasing colorectal cancer screening rates has been a priority in the United States for some time, as outcomes have been shown to improve significantly when asymptomatic polyps and other early-stage cancers are detected and treated early. EarlySign is pleased to support the collective efforts of Capital Digestive Care, the largest private gastroenterology (GI) practice in the Mid-Atlantic region, as they recently announced the launch of EarlySign’s LGI-Flag in the United States. Available through the Roche navify® Algorithm Suite, LGI-Flag is a groundbreaking AI-driven algorithm used to flag individuals at risk for lower GI disorders that warrant further evaluation.  https://lnkd.in/gpet5JVw

EarlySign salutes our colleague and innovation partner, David Vawdrey, PhD, chief data and informatics officer at Geisinger as he will be part of an exceptional panel of industry and clinical leaders at HIMSS entitled, “Elevating Clinical Excellence through Innovative algorithms and Clinical Decision Support.” #AIML #algorithms #healthtech #earlydetection

With #Colorectalcancer Awareness Month approaching, we appreciate the diligence of the clinicians, care givers and healthcare organizations who are striving to help promote the urgency around prevention, screening, and early detection of CRC. https://lnkd.in/gJcjHzYZ #earlydetection